Validation and digital implementation of the HADES score for hereditary angioedema

Background Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is frequently misdiagnosed, leading to delayed diagnosis and inappropriate management. We previously developed a predictive clinical score (HADES) to support early identification of patients at risk for HAE-C1-INH. Objective To evaluate the temporal performance of HADES in a new cohort of patients with suspected HAE-C1-INH and explore the feasibility of its digital implementation in a small prospective pilot study. Methods A total of 539 individuals with suspicion of HAE-C1-INH were evaluated. HADES scores were calculated using the previously predefined thresholds, and diagnostic performance and ROC analyses were compared with the derivation cohort. In parallel, a prospective pilot study using the HADES App was conducted in 18 patients to assess its implementation feasibility. In addition, 6 patients with HAE-FXII were analyzed separately for exploratory purposes. Results The validation cohort reproduced key performance characteristics of the original model. Sensitivity remained 100% at low thresholds, specificity increased across score categories, and no confirmed HAE-C1-INH cases occurred in score category 0. The AUC was 0.80 (95% CI, 0.73-0.86), matching the derivation dataset. The exploratory HADES-App cohort provided preliminary information on digital implementation feasibility. Patients with HAE- FXII showed score distributions overlapping those of HAE-C1-INH cases. Conclusion In a temporal validation cohort, HADES demonstrated discriminative performance consistent with the original study and reasonable overall category-level calibration, supporting its potential role as a clinical screening tool for HAE-C1-INH. Preliminary digital implementation findings warrant further prospective evaluation.

Authors

Institutions

Publication Details

Journal
Frontiers in Epidemiology
Published
2026-11-12
DOI
https://doi.org/10.3389/fepid.2026.2000978
Primary Topic
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Validation and digital implementation of the HADES score for hereditary angioedema

Ricardo Dario Zwiener, Andrea Pino, Rafael J. Zamora, Carlos María Galmarini et al.
Frontiers in Epidemiology
Coagulation, Bradykinin, Polyphosphates, and Angioedema
article

Validation and digital implementation of the HADES score for hereditary angioedema

Ricardo Dario Zwiener, Andrea Pino, Rafael J. Zamora, Carlos María Galmarini, Laura Brion, Paula Adriana Rozenfeld, Laura Castro Labrador
article en

Abstract

Background Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is frequently misdiagnosed, leading to delayed diagnosis and inappropriate management. We previously developed a predictive clinical score (HADES) to support early identification of patients at risk for HAE-C1-INH. Objective To evaluate the temporal performance of HADES in a new cohort of patients with suspected HAE-C1-INH and explore the feasibility of its digital implementation in a small prospective pilot study. Methods A total of 539 individuals with suspicion of HAE-C1-INH were evaluated. HADES scores were calculated using the previously predefined thresholds, and diagnostic performance and ROC analyses were compared with the derivation cohort. In parallel, a prospective pilot study using the HADES App was conducted in 18 patients to assess its implementation feasibility. In addition, 6 patients with HAE-FXII were analyzed separately for exploratory purposes. Results The validation cohort reproduced key performance characteristics of the original model. Sensitivity remained 100% at low thresholds, specificity increased across score categories, and no confirmed HAE-C1-INH cases occurred in score category 0. The AUC was 0.80 (95% CI, 0.73-0.86), matching the derivation dataset. The exploratory HADES-App cohort provided preliminary information on digital implementation feasibility. Patients with HAE- FXII showed score distributions overlapping those of HAE-C1-INH cases. Conclusion In a temporal validation cohort, HADES demonstrated discriminative performance consistent with the original study and reasonable overall category-level calibration, supporting its potential role as a clinical screening tool for HAE-C1-INH. Preliminary digital implementation findings warrant further prospective evaluation.

Frontiers in EpidemiologyVol. 6
Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Takeda (Singapore) (SG), Hospital Universitario Austral (AR), Universidad Nacional de La Plata (AR)
Takeda Pharmaceutical Company
Good health and well-being
Coagulation, Bradykinin, Polyphosphates, and Angioedema
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon